

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

JAN 29 2002

1

## Complete if Known

Application Number	08/851,965
Filing Date	May 6, 1997
First Named Inventor	Andrew A. Young
Group Art Unit	1627 1639
Examiner Name	B. Celsa
Attorney Docket Number	030639.0053.CPA1

TECH CENTER 1600/2900

FEB 06 2002

RECEIVED

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	6,114,304		Kolterman, et al.	09/05/2000	11
	AB	5,795,861		Kolterman, et al.	08/18/1998	11
	AC	5,686,411		Gaeta, et al.	11/11/1997	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AD	WO	95/07098	A1	Amylin Pharmaceuticals, Inc.	03/16/1995		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AE	BEAUMONT, et al., "High Affinity Amylin Binding Sites in Rat Brain," <u>Molecular Pharmacology</u> , 44:493-497 (1993)	
	AF	GRAY, et al., "A Role for Calcitonin Gene-Related Peptide in Protection Against Gastric Ulceration," <u>Annals of Surgery</u> , 219(1):58-64 (1994) - ABSTRACT	
	AG	HARTTER, et al., "Basal and Stimulated Plasma Levels of Pancreatic Amylin Indicate its Co-secretion with Insulin in Humans," <u>Diabetologia</u> , 34:52-54 (1991)	
	AH	MAGGI, et al., "Anti-ulcer Activity of Calcitonin Gene-Related Peptide in Rats," <u>Gen. Pharmacol.</u> , 18(1):33-34 (1987) - ABSTRACT	
	AI	MILLER, et al., "Calcitonin Gene-Related Peptide (CGRP) Upregulates the Restitution of Rat Gastric Mucosa In Vitro," <u>Journal of Surgical Research</u> , 58(4):421-424 (1995) - ABSTRACT	


Examiner Signature		Date Considered	314104
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	08/851,965
Filing Date	May 6, 1997
First Named Inventor	Andrew A. Young
Group Art Unit	1627 1634
Examiner Name	B. Celsa

Attorney Docket Number 030639.0053.CPA1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
-------------------	-----------------------	---

<i>AC</i>	AJ	PITTNER, "Lack of Effect of Calcitonin Gene-Related Peptide and Amylin on Major Markers of Glucose Metabolism in Hepatocytes," <u>European Journal of Pharmacology</u> , 325:189-197 (1997)
	AK	TACHE, "Inhibition of Gastric Acid Secretion and Ulcers by Calcitonin Gene-Related Peptide," <u>Ann. N.Y. Acad. Sci.</u> , 657:240-247 (1992)
	AL	YOUNG, et al., "Preclinical Pharmacology of Pramlintide in the Rat: Comparisons With Human and Rat Amylin," <u>Drug Development Research</u> , 37:231-248 (1996)
<i>AL</i>	AM	YOUNG, et al., " <sup>18-37</sup> hCGRP, an Amylin Receptor Antagonist, Enhances the Insulin Response and Perturbs the Glucose Response to Infused Arginine in Anesthetized Rats," <u>Molecular and Cellular Endocrinology</u> , 84:R1-R5 (1992)

Examiner Signature	<i>AC</i>	Date Considered	2/4/04
--------------------	-----------	-----------------	--------

TECH CENTER 1600/2900

FEB 06 2002

RECEIVED